Diane L Reidy-Lagunes
Affiliation: Memorial Sloan-Kettering Cancer Center
- Treatment of advanced disease in patients with well-differentiated neuroendocrine tumorsDiane L Reidy
Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
Nat Clin Pract Oncol 6:143-52. 2009..We will discuss the data on therapies currently used to treat well-differentiated NETs, and the strategies being used in clinical trials...
- Systemic therapy for advanced pancreatic neuroendocrine tumors: an updateDiane L Reidy-Lagunes
Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill College of Medicine, Cornell University, New York, NY, USA
J Natl Compr Canc Netw 10:777-83. 2012..This article discusses these recent trials and provides an update of systemic treatment options in patients with well-differentiated pancNETs...
- Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?Diane Reidy-Lagunes
Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Curr Oncol Rep 14:249-56. 2012..Such a discovery could potentially be used to stratify treatment and such studies are currently being investigated...
- Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancerDiane Lauren Reidy
Department of Medicine, Division of Solid Tumors, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1004, New York, NY 10065, USA
J Clin Oncol 28:4240-6. 2010....
- A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumorsDiane L Reidy-Lagunes
Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 118:4795-800. 2012..Therefore, the authors of this report evaluated the safety and efficacy of MK-0646, a fully human monoclonal antibody (MoAb) that binds to the IGF-1R, as monotherapy in patients with metastatic, well-differentiated NETs...
- Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trialDeborah Schrag
All authors Memorial Sloan Kettering Cancer Center, New York, NY
J Clin Oncol 32:513-8. 2014..We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with selective rather than consistent use of chemoradiotherapy...
- Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing PanelsZsofia K Stadler
Zsofia K Stadler, Francesca Battaglin, Sumit Middha, Jaclyn F Hechtman, Christina Tran, Andrea Cercek, Rona Yaeger, Neil H Segal, Anna M Varghese, Diane L Reidy Lagunes, Nancy E Kemeny, Erin E Salo Mullen, Asad Ashraf, Martin R Weiser, Julio Garcia Aguilar, Mark E Robson, Kenneth Offit, Maria E Arcila, Michael F Berger, Jinru Shia, David B Solit, and Leonard B Saltz, Memorial Sloan Kettering Cancer Center, New York, NY and Francesca Battaglin, Veneto Institute of Oncology, Padua, Italy
J Clin Oncol 34:2141-7. 2016....
- Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancerAndrea Cercek
From the aGastrointestinal Oncology Service, Department of Medicine, bDepartment of Radiation Therapy, and cColorectal Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
J Natl Compr Canc Netw 12:513-9. 2014..FOLFOX and chemoradiation before planned TME results in tumor regression, a high rate of delivery of planned therapy, and a substantial rate of pathCRs, and offers a good platform for nonoperative management in select patients. ..
- Bevacizumab 5 mg/kg can be infused safely over 10 minutesDiane L Reidy
Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:2691-5. 2007..We sought to determine if the initial prolonged infusion was still necessary and if an infusion time of fewer than 30 minutes could be safely used...
- Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control StudyEran Sadot
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Surg Oncol 23:1361-70. 2016..Management approach for small PanNET is uncertain...
- A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinomaGhassan K Abou-Alfa
Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States Electronic address
J Hepatol 60:319-24. 2014..IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study...
- Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liverJoseph P Erinjeri
Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cardiovasc Intervent Radiol 33:610-4. 2010....